Loading use case index…
Loading use case index…
AI use case
Exscientia, an Oxford-based AI drug discovery company, applied its AI-driven platform to respiratory disease drug discovery. The company's automated systems and machine learning…
Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.
Every column from the source row, in stable order. URLs open in a new tab.
Title
AI for Respiratory Drug Discovery
Content
Exscientia, an Oxford-based AI drug discovery company, applied its AI-driven platform to respiratory disease drug discovery. The company's automated systems and machine learning algorithms enabled rapid identification of optimized compounds for respiratory conditions. Exscientia's approach combined phenotypic screening with AI-driven design to generate novel compounds addressing unmet medical needs in respiratory diseases. The AI platform continuously learned from experimental data to improve compound predictions. In 2021, Exscientia announced a collaboration using their AI platform for virus protease inhibitor design, demonstrating broad applicability across respiratory and infectious diseases. Note: Exscientia merged with Recursion in 2024.
Continue exploring AI deployments in the catalog.
Back to use casesCity
Oxford
Company/Organization
AstraZeneca
Continent
Europe
Country
United Kingdom
Category
Pharmaceuticals
Type
Deployment
Id
6d8fded2-f23a-4673-bff2-885620dfe310
Created At
2026-03-22T22:27:10.085+00:00